Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Trial Profile

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jun 2018 Planned End Date changed from 1 Jun 2019 to 11 Jun 2019.
    • 17 Jun 2018 Planned primary completion date changed from 1 Jun 2019 to 11 Jun 2019.
    • 17 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top